Regulations.gov document
Reference 13 - ISMP Remdesivir Investigational Drug Labeling Confusion 2020 re: Potential…
Supporting & Related Material · FDA-2021-N-0127 · posted Mar 18, 2021
Key facts
| Document ID | FDA-2021-N-0127-0009 |
|---|---|
| Title | Reference 13 - ISMP Remdesivir Investigational Drug Labeling Confusion 2020 re: Potential Medication Error Risks With Investigational Drug Container Labels; Public Meeting; Request for Comments |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2021-N-0127 |
| Posted | Mar 18, 2021 |
At a glance
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: